For improving the cancer diagnosis and management capabilities of the pathological condition, this signature biomarker (MUC3A/MUC4/MUC13/MUC16) plays a constructive role by enabling the real‐time monitoring through the noninvasive technique, paving the path for better patient outcomes through early diagnosis and targeted treatment methods. This evidence concerns the gene MUC4 and cancer.